ArticleJTCVS open2026
Endoscopic findings predictive of pathologic upstaging in T2N0 esophageal cancer.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Endoscopic ultrasound (EUS) evaluation of T2N0 esophageal cancers is associated with high rates of staging inaccuracy, impacting whether induction therapy is appropriately selected for these patients. We aimed to identify whether tumor appearance on endoscopy can predict whether preoperative EUS staging appropriately directs management. Methods: The impact of tumors being described on endoscopic reports as bulky, ulcerative, or obstructive on the accuracy of EUS staging for patients with cT2N0 esophageal cancer who underwent esophagectomy without induction therapy at a single institution between 2008 and 2024 was evaluated with χ Results: Of 35 patients with cT2N0 esophageal cancer who underwent esophagectomy without induction therapy, 57.1% (20/35) patients had pT1-2N0 pathology after esophagectomy. Conversely, 42.9% (15/35) of patients were understaged by EUS. There was a significant association between EUS accuracy and tumors endoscopically described as bulky, ulcerative, or obstructive ( Conclusions: Patients with cT2N0 esophageal cancer by EUS are likely to be understaged when the tumor endoscopic appearance is bulky, ulcerative, or obstructive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.